Malaria is a major cause of anaemia in tropical areas. Malaria infection causes haemolysis
of infected and uninfected erythrocytes and bone marrow dyserythropoiesis which …

Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …

Background Severe malaria is a major cause of childhood death and often the main reason
for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established …

Parasite clearance data from 18,699 patients with falciparum malaria treated with an
artemisinin derivative in areas of low (n= 14,539), moderate (n= 2077), and high (n= 2083) …

Background Achieving adequate antimalarial drug exposure is essential for curing malaria.
Day 7 blood or plasma lumefantrine concentrations provide a simple measure of drug …

Background Imperfect adherence is a major barrier to effective primaquine radical cure of
Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P …

Background A 14-day course of primaquine is used for radical cure of Plasmodium vivax
and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after …

Background WHO recommends gametocytocidal, single low-dose primaquine for blocking
the transmission of Plasmodium falciparum; however, safety concerns have hampered the …

Background The fixed dose combination of artemether-lumefantrine (AL) is the most widely
used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure …

Preoperative risk assessment is essential for shared decision-making and adequate
perioperative care. Common scores provide limited predictive quality and lack personalized …